Page last updated: 2024-11-13
syringolin a
Description
syringolin A: a cyclic dipeptide composed of the two non-proteinogenic amino acids [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
syringolin A : A syrbactin that has a (3E,9E)-2,7-dioxo-1,6-diazacyclododeca-3,9-diene skeleton that is substituted by an isopropyl group at position 5 and by a [(2S)-2-({[(1S)-1-carboxy-2-methylpropyl]carbamoyl}amino)-3-methylbutanoyl]nitrilo group at the 8-pro-S position. It is produced by the pathogenic bacterium Pseudomonas syringae pv. syringae. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (6)
Synonym |
2-[[1-[[(3e,9e)-2,7-dioxo-5-propan-2-yl-1,6-diazacyclododeca-3,9-dien-8-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoylamino]-3-methylbutanoic acid |
CHEBI:181397 |
2-(3-(1-(((4e,10e)-2,9-dioxo-12-isopropyl-1,8-diazacyclododecane-4,10-diene-3-yl)carbamoyl)-2-methylpropyl)ureido)-3-methylbutyric acid |
syringolin a |
212115-96-3 |
AKOS040735349 |
Research Excerpts
Overview
Syringolin A (SylA) is a nonribosomal cyclic peptide. It is produced by the bacterial pathogen Pseudomonas syringae pv syringAE that can inhibit the eukaryotic proteasome. Syringsolin A was shown to be a virulence factor for P.syringae.
Excerpt | Reference | Relevance |
"Isosyringolin A, which is an isomer of the proteasome-inhibiting natural product syringolin A, was designed and synthesized to develop analogues that are step economical and synthetically accessible in a practical manner. " | ( Design, Synthesis, and Biological Activity of Isosyringolin A. Chiba, T; Ichikawa, S; Iida, S; Kitahata, S; Matsuda, A; Ri, M; Yoshida, T, 2016) | 1.31 |
"Syringolin A was shown to be a virulence factor for P." | ( Pseudomonas syringae virulence factor syringolin A counteracts stomatal immunity by proteasome inhibition. Dudler, R; Ramel, C; Schellenberg, B, 2010) | 1.35 |
"Syringolin A (SylA) is a nonribosomal cyclic peptide produced by the bacterial pathogen Pseudomonas syringae pv syringae that can inhibit the eukaryotic proteasome. " | ( Proteasome activity imaging and profiling characterizes bacterial effector syringolin A. Clerc, J; Gu, C; Kaiser, M; Kaschani, F; Kolodziejek, I; Krahn, D; Misas-Villamil, JC; Niessen, S; Overkleeft, HS; van der Hoorn, RA; Verdoes, M; Willems, LI, 2011) | 2.04 |
"Syringolin A is an unusual derivative of a tripeptide that contains a 12-membered ring consisting of the amino acids 5-methyl-4-amino-2-hexenoic acid and 3,4-dehydrolysine, two nonproteinogenic amino acids." | ( Functional analysis of genes involved in the synthesis of syringolin A by Pseudomonas syringae pv. syringae B301 D-R. Amrein, H; Dudler, R; Granado, J; Makart, S; Schneider-Pokorny, J; Shakya, R, 2004) | 1.29 |
"Syringolin A is a new plant elicitor produced by the plant pathogen Pseudomonas syringae pv. " | ( Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis. Bachmann, AS; Coleman, CS; Dudler, R; Michel, K; Park, DJ; Rocetes, JP; Wallick, CJ; Warn-Cramer, BJ, 2006) | 3.22 |
Drug Classes (1)
Class | Description |
dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (39)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (23.08) | 29.6817 |
2010's | 28 (71.79) | 24.3611 |
2020's | 2 (5.13) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.04
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.04 (24.57) | Research Supply Index | 3.69 (2.92) | Research Growth Index | 4.73 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (7.69%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 36 (92.31%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |